Views: 0 Author: Site Editor Publish Time: 2026-03-20 Origin: Site
By 2026, the tablet press market is shifting fast. It’s moving from pure mechanics to digital assets.
That changes what buyers value.
BIOBASE is riding two waves at once. Traditional Chinese medicine modernization is one. Premium supplements are the other.
Custom vitamins are a great example.
Today, buyers don’t only ask “tablets per hour.” They ask about data compliance and footprint efficiency.
That’s the new filter.
BIOBASE models often split into two families. One is BK-TPM for manual presses. The other is BK-APM for automatic systems.
It’s a simple lineup logic.
| Model | Machine Type | Max Pressure | Max Output | Best Use Case |
|---|---|---|---|---|
| BK-TPM10 | Manual single-punch | 15 kN | ~2,000 pcs/h | Ultra-light bench unit for clinics and teaching labs |
| BK-APM40 | Automatic hydraulic press + PLC | 40T (400 kN) | Cycle-based pressing | One-click pressing, demolding, and reset for lab workflows |
| THT series | Tablet hardness tester | - | - | Hardness testing for consistent product release |
BK-APM40 is explicitly described with a PLC touch screen and one-click operation. It also lists 40T (400 kN) max pressure.
The THT series is positioned for measuring tablet breaking strength. It highlights an LCD display and a high-precision pressure sensor.
BK-TPM10 is commonly listed with 15 kN max pressure and about 2,000 pcs/h output. Those numbers depend on hand-crank speed. Source
Forward-looking note: a “Cloud-Series” style upgrade is plausible. IoT pressure-curve monitoring is the obvious next step.
It’s where lab buyers are heading.
Small R&D labs (annual output < 100,000 tablets)
Your pain is space. Your powder is expensive.
Go with BK-TPM10 for fast trials and low waste.
Mid-size pharma or CMO pilots (annual output 100,000–500,000 tablets)
Your pain is labor cost. Consistency becomes the bottleneck.
Consider BK-APM40 if one-click automated pressing fits your workflow.
In 2026, BIOBASE press pricing is often discussed in the $1,500–$4,500 range. It varies by configuration and channel.
But the smarter way is TCO.
A practical TCO model looks like this:
TCO = P_purchase + (F_freight × (1 + T_tariff)) + (O_ops × Y)
P is purchase price. F is freight. T is tariff. O is annual upkeep. Y is service years.
Durability lowers O over time.
BIOBASE shines in “lab minimalism.” It’s clean and straightforward.
It gets you from 0 to 1.
When you move toward pre-production, Hanyoo’s pitch gets louder. It’s about throughput and automation depth.
It pushes you from 1 to 100.
Automation range: single-punch systems tend to top out early. Hanyoo’s smart VFD approach targets higher steady output.
It’s built for scale.
Pressure headroom: Hanyoo often markets higher tonnage options. That can matter for very hard tablets and special materials.
Think ceramics or acidic candy tablets.
Case-style takeaway: some teams validate formulas on BIOBASE first. Then they scale on a higher-throughput Hanyoo line.
That “test then ramp” workflow is pretty common.
Set a hard capacity line: if you need more than 50 tablets per minute, plan for automation.
Manual workflows will hurt later.
Verify material fit: ask for a pressure-to-hardness curve using your actual powder.
Don’t accept generic demo material.
Run a compliance check: confirm you can export data for audits. GMP reviews are getting more digital.
You’ll be glad you asked early.
Q: What are the main BIOBASE models to watch?
A: The headline picks are BK-TPM10 and BK-APM40. BK-TPM10 is often listed as a compact manual unit. BK-APM40 is positioned with PLC touchscreen control and one-click pressing. Source Source
Q: How strong is BIOBASE on price in 2026?
A: It’s typically cheaper than premium imported lab brands. It’s usually pricier than generic no-name single-punch units.
The premium is often justified by controls and support expectations.
